Value through InnovationJuly 23 2014

U.S. Journalist and Media Contact Information

The contacts listed below are for use by representatives of the news media. If you are not a member of the media and need assistance, we ask that you please contact the company at 1-800-243-0127, Monday through Friday from 8:30 a.m. to 5:00 p.m., excluding holidays.

This contact information is not intended for reporting unexpected drug effects or adverse events for any Boehringer Ingelheim product. Please report any unexpected effects or product problems to the Drug Information Unit by calling 1-800-542-6257 (option 4).

U.S. Headquarters Contact Information

  • Boehringer Ingelheim Pharmaceuticals, Inc.

    900 Ridgebury Rd.
    P.O. Box 368
    Ridgefield, CT 06877

U.S. Corporate Media Inquiries

  • Media Contact - Public Affairs & Communications

    Erin Crew

    Boehringer Ingelheim Pharmaceuticals, Inc

U.S. Products and Pipeline Media Inquiries - General

  • Media Contact - U.S. Prescription Medicines, Therapeutic Areas & Pipeline

    Kate O'Connor

    Boehringer Ingelheim Pharmaceuticals, Inc

U.S. Products by Therapeutic Area

  • Media Contact - Cardiovascular

    Mary Lewis

    Pradaxa® (dabigatran etexilate mesylate) capsules

  • Media Contact - Diabetes

    Emily Baier

    Jentadueto® (linagliptin and metformin hydrochloride) tablets

    Tradjenta® (linagliptin) tablets

    empagliflozin (investigational)

    empagliflozin + metformin (investigational)

    empagliflozin + linagliptin (investigational)

  • Media Contact - Diabetes

    Shirley Johnson

    Jentadueto® (linagliptin and metformin hydrochloride) tablets

    Tradjenta® (linagliptin) tablets

    empagliflozin (investigational)

    empagliflozin + metformin (investigational)

    empagliflozin + linagliptin (investigational)

  • Media Contact - Oncology & Virology

    Susan Holz

    Oncology
    Early pipeline
    nintedanib (investigational)

    Virology
    faldaprevir (investigational)

  • Media Contact - Oncology

    Paul Wynn

    Gilotrif® (afatinib) tablets

    volasertib (investigational)

  • Media Contact - Respiratory

    Jennifer Forsyth

    Atrovent® HFA (ipratropium bromide HFA) Inhalation Aerosol

    Combivent® Respimat® (ipratropium bromide and albuterol)

    Spiriva® HandiHaler® (tiotropium bromide inhalation powder)

    nintedanib (investigational)

    olodaterol (investigational)

    tiotropium (investigational)

    tiotropium + olodaterol (investigational)

U.S. Consumer Health Care Inquiries

  • Media Contact - Consumer Health Care

    Erin Crew

    Boehringer Ingelheim Pharmaceuticals, Inc

International Contact

  • Our Vision
    Boehringer Ingelheim GmbH

    Corporate Division Communications
    Binger Strasse 173
    D-55216 Ingelheim am Rhein
    Germany